At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in 
Europe, which has gathered 28k participants from 167 countries, many 
discussions will be around sustainability, prevention and novel approaches 
which could soon become a reality in the clinic.

- Late-breaking results elucidate the link between air pollution and lung 
cancer in people who have never smoked
“Pollution has a known association with lung cancer, but we didn’t know if and 
how it directly causes the disease” - Scientific Co-chair Charles Swanton, 
Francis Crick Institute, UK. These results begin to explain how environmental 
carcinogens can drive cancer, deriving a public health mandate to lower the 
levels of these pollutants, produced by the combustion of fossil fuels. “We 
have to achieve a 50% reduction in greenhouse gas emissions by 2030, by doing 
so we will naturally reduce levels of PM2.5. We can all play a part: we need to 
cycle more, walk more. PM2.5 cause 8 million deaths a year, not just due to 
cancer but also to other diseases, i.e., more than the deaths caused by tobacco 
globally.”

- Study confirms accuracy of multi-cancer early detection blood testing, 
possibly leading to major paradigm shift in screening and early detection
“This is one of the very first studies where the detection of cancer DNA in the 
blood has allowed to detect cancer at an early stage” - Scientific Co-Chair 
Fabrice Andre, Gustave Roussy, France. “If this test works, in the future it 
will be good news for patients. But with this comes a wake-up call for 
hospitals to see what will happen in 10 years and start now to train fellows 
and change infrastructures accordingly.” 

- Other highly anticipated results to be presented at the ESMO Congress 2022 
Phase III trial of first-in-class drug targeting a new molecular alteration in 
a rare category of cancers; landmark trial of cell therapy using tumour 
infiltrating lymphocytes to improve outcomes for advanced melanoma; several 
late-phase trials of immunotherapy, including for non-small cell lung cancer 
not eligible to standard chemotherapy; studies for underrepresented patient 
populations 


Full story: https://bit.ly/3B2pJ2f 
For more: press@esmo.org
#ESMO22

ESMO is the leading professional organisation for medical oncology, with 25k 
members represent-ing oncology professionals in 160 countries worldwide 
www.esmo.org 
  
Contact:

Vanessa Pavinato
+41 91 973 19 01
press@esmo.org

Source: European Society for Medical Oncology (ESMO)